Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
SAN CLEMENTE, Calif., June 01, 2017 -- David Steenblock, an osteopathic physician based in San Clemente, CA, is uniquely qualified to address toxicity in the human body through his use of EDTA Chelation Therapy.
Dr. Steenblock uses EDTA (EthyleneDiamineTetraAcetic Acid) Chelation Therapy, a procedure that removes heavy metals from the blood, and consistently improves blood flow and relieves symptoms associated with atherosclerosis in over 80% of patients treated.
“It’s been observed that patients being treated for acute lead intoxification with EDTA with cardiovascular disease, showed improved stress tolerance and less chest pain with physical exertion, “ said Dr. Steenblock.
Dr. Steenblock believes that the benefits of EDTA chelation can improve circulation; reduce cholesterol levels, decrease high blood pressure; and lower insulin requirements in diabetics.
In addition, Dr. Steenblock uses EDTA Chelation Therapy with a combination of hyperbaric oxygen therapy, leading to significant neurologic improvements for stroke patients.
Dr. David Steenblock is a leading-edge physician in many fields of medicine, from stroke care, to acute brain trauma, to generative and cell-based medicine in the treatment of ALS, Cerebral Palsy and other chronic and degenerative diseases. For more information about Dr. Steenblock’s work in stem cell therapies, visit www.stemcellmd.org.
CONTACT: Irene Doti [email protected]
